Intracellular delivery of VEGF165 encoding gene therapeutic using trifunctional copolymers of ethylene oxide and propylene oxide by Bondar O. et al.
Intracellular delivery of VEGF165 encoding gene therapeutic
using trifunctional copolymers of ethylene oxide and propylene
oxide
Oksana Bondar a, Vesta Shevchenko a, Alina Martynova a, Diana Salakhieva a, Irina Savina b,
Yurii Shtyrlin a, Timur Abdullin a,⇑
aCenter for Pharmaceutical Research and Education, Kazan (Volga Region) Federal University, 18 Kremlyovskaya St., 420008 Kazan, Russia
b School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road, Brighton BN2 4GJ, UK
a r t i c l e i n f o
Article history:
Received 28 October 2014
Received in revised form 17 February 2015
Accepted 7 March 2015
Available online 26 March 2015
Keywords:
Trifunctional copolymers of propylene oxide
and ethylene oxide
Pluronics
Polymer-mediated gene therapy
Plasmid DNA
Neovasculgen
VEGF165
a b s t r a c t
New type of copolymers of propylene oxide and ethylene oxide was assessed for promoting
delivery of plasmid DNA based gene therapeutics. Lipid-like trifunctional copolymers
(TFCs), with both random or diblock structures and relatively low hydrophilic–lipophilic
balance, were studied and compared with linear Pluronic™ L61. Structure-dependent
relationships for micelle-forming, cytotoxic and hemolytic properties of these copolymers
were revealed. The TFC with the mean number of propylene oxide and ethylene oxide units
of 83.5 and 24.2, respectively, exhibited relatively low adverse effects in vitro. The latter
TFC interacted with plasmid DNA–polyethyleneimine complexes and improved their intra-
cellular delivery. Furthermore, this TFC efﬁciently promoted the transfection of dermal
ﬁbroblasts with VEGF165-encoding Neovasculgen plasmid DNA, which has been clinically
used for the therapeutic angiogenesis. Our ﬁndings demonstrated for the ﬁrst time that
TFCs are promising for the polymer-mediated delivery of gene therapeutics.
 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Gene therapeutics are promising biologics which have
been engineered to treat a host of monogenic and complex
diseases including neurodegenerative, cardiovascular and
cancer ones [1]. The main engineering platforms for gene
therapeutics include synthetic oligonucleotides, viruses
and plasmid DNAs (pDNA) [1,2], the two latter types are
considered ‘pro-drugs’ that allow for a template-directed
synthesis of a desired peptide within the cell. Compared
to viruses, pDNA has a great advantage in clinical applica-
tion due to its intrinsic safety, low cost and vector capacity.
However, pDNA itself suffers from its poor intracellular
penetration and stability [3].
Several pDNAs encoding bioactive peptides have been
developed and studied as potential drugs in different appli-
cations, e.g. for: therapeutic angiogenesis, regeneration of
peripheral nerves and bones (see review [4]), cancer treat-
ment [5], and DNA vaccination [6]. However, the improve-
ment of intrinsically low pDNA transfection efﬁciency
remains relevant and unresolved biomedical task. The
common approach exploits various cationic lipids and
polymers, both of synthetic and natural origin, which bind
to, condense and neutralize nucleic acids, thereby improv-
ing their stability and cellular pharmacokinetics [2,4].
While cationic carriers of pDNA exhibit a relatively high
efﬁciency in vitro, their gene therapy applications are
strictly restricted, due to membrane-damaging and cyto-
toxic properties of polycations [2,7]. To overcome this
problem, new polymeric systems that deliver pDNA, both
alone and combined with polycations, have been proposed.
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